Marcus Schmidt
A5059885667- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Breast Lesions and Carcinomas
- Gene expression and cancer classification
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Bioinformatics and Genomic Networks
- Immunodeficiency and Autoimmune Disorders
- Urticaria and Related Conditions
- Molecular Biology Techniques and Applications
- Cancer Research and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
University Medical Center of the Johannes Gutenberg University Mainz
2016-2025
Johannes Gutenberg University Mainz
2016-2025
Sana Klinikum Offenbach
2016-2025
Klinik für Frauenheilkunde
2010-2024
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie
2015-2024
Universitäts Frauenklinik
2019-2024
Max Rubner Institut
2024
Charité - Universitätsmedizin Berlin
2014-2023
Thurgau University of Teacher Education
2022
Metalsa (Germany)
2020
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) immunologically relevant genes neoadjuvant GeparSixto trial. Patients Methods investigated effect adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response...
Abstract Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional motifs, we analyzed the gene patterns of 200 tumors patients who were not treated by systemic therapy after surgery using discovery approach. After performing hierarchical cluster analysis, identified coregulated genes related to biological process proliferation, steroid hormone expression, as well B-cell T-cell infiltration. We calculated...
According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used assist in making treatment decisions after consideration conventional markers. We developed and validated a gene expression signature likelihood distant recurrence with estrogen receptor (ER)-positive, HER2-negative treated adjuvant endocrine therapy.RNA levels assessed by quantitative reverse transcriptase PCR formalin-fixed, paraffin-embedded tumor tissue were calculate risk score...
Purpose Trastuzumab shows clinical activity in human epidermal growth factor receptor 2 (HER-2)–positive early and advanced breast cancer. In the German Breast Group 26/Breast International 03-05 trial, we investigated if trastuzumab treatment should be continued beyond progression. Methods Patients with HER-2–positive cancer that progresses during were randomly assigned to receive capecitabine (2,500 mg/m body-surface area on days 1 through 14 [1,250 semi-daily]) alone or continuation of (6...
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
ER+/HER2- breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years endocrine treatment can improve patient selection extended hormonal therapy.A total 1702 postmenopausal cancer patients from two adjuvant phase III trials (ABCSG6, ABCSG8) treated with therapy participated in this study. The multigene test EndoPredict (EP) and the EPclin score (which combines EP tumour size nodal status) were predefined independent training cohorts. All...
Abstract Introduction Current prognostic gene expression profiles for breast cancer mainly reflect proliferation status and are most useful in ER-positive cancers. Triple negative cancers (TNBC) clinically heterogeneous markers biology-based therapies needed to better treat this disease. Methods We assembled Affymetrix data 579 TNBC performed unsupervised analysis define metagenes that distinguish molecular subsets within TNBC. used n = 394 cases discovery 185 validation. Sixteen emerged...
Abstract Purpose: Although the central role of immune system for tumor prognosis is generally accepted, a single robust marker not yet available. Experimental Design: On basis receiver operating characteristic analyses, markers were identified from 60-gene B cell–derived metagene and analyzed in gene expression profiles 1,810 breast cancer; 1,056 non–small cell lung carcinoma (NSCLC); 513 colorectal; 426 ovarian cancer patients. Protein RNA levels examined paraffin-embedded tissue 330 The...
Several studies suggest a link between circadian rhythm disturbances and tumorigenesis. However, the association clock genes prognosis in breast cancer has not been systematically studied. Therefore, we examined expression of 17 components tumors from 766 node-negative patients that were untreated both neoadjuvant adjuvant settings. In addition, their with metastasis-free survival (MFS) correlation to clinicopathological parameters investigated. Aiming estimate functionality clockwork,...
Importance Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, non-Hispanic Black women, and risk of progression to metastatic cancer, devastating sequela 12- 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative was chemotherapy after surgery. However, it not known whether the addition immune therapy postsurgery would be beneficial. Objective To evaluate form atezolizumab postoperative patients high-risk...
Abstract Reactive oxygen species are potentially damaging molecules. An important function of antioxidants is to intercept harmful triplet states, in order prevent the formation singlet oxygen, or quench directly. However, also reactive towards other active such as hydroxyl radical, superoxide anion and non‐excited ground state presence radical initiators. It well known that flavonoids carotenoids show strong antioxidant properties. Polyenes best among compounds by efficient energy transfer....
Activated protein C (APC) protects against sepsis in animal models and inhibits the lipopolysacharide (LPS)-induced elaboration of proinflammatory cytokines from monocytes. The molecular mechanism responsible for this property is unknown. We assessed effect APC on LPS-induced tumour necrosis factor alpha (TNF-alpha) production activation central transcription nuclear factor-kappaB (NF-kappaB) a THP-1 cell line. Cells were preincubated with varying concentrations (200 microg/ml, 100 microg/ml...
Abstract Introduction The purpose of this work was to study the prognostic influence in breast cancer thioredoxin reductase 1 (TXNRD1) and interacting protein (TXNIP), key players oxidative stress control that are currently evaluated as possible therapeutic targets. Methods Analysis association TXNRD1 TXNIP RNA expression with metastasis-free interval (MFI) performed 788 patients node-negative cancer, consisting three individual cohorts (Mainz, Rotterdam Transbig). Correlation metagenes...
In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated accurately assess prognosis in this population. study, clinical relevance of EPclin relation well-established guidelines assessed.We assigned risk groups 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine...
Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival (PFS) compared alone as first-line treatment estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, advanced breast cancer (20.2 months versus 10.2 months; hazard ratio (HR) = 0.488, 95 % confidence interval (CI) 0.319–0.748; one-sided p...